Precision BioSciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Precision BioSciences Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- DTIL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001357874
Board of directors
-
Geno J. Germano · DirectorSince 2023
-
Kevin Buehler · DirectorSince 2023
-
Melinda Brown · DirectorSince 2023
-
Michael Amoroso · Director · President and CEOSince 2023
-
Samuel C. Wadsworth · DirectorSince 2023
-
Shari Lisa Pire · DirectorSince 2023
-
Stanley Frankel · DirectorSince 2023
Chief executives
Michael Amoroso
· President and CEO
Dates unknown
Board connections
2 of this board's directors also sit on 3 other boards.
- via Michael Amoroso
- via Geno J. Germano
- via Geno J. Germano
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $33,714
- 3 purchases by 3 insiders
- Sold, last 12 months
- $466,167
- 11 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 20, 2026 | Kevin Buehler Director | Option exercise | +21,000 | — | — |
| May 20, 2026 | Stanley Frankel Director | Option exercise | +21,000 | — | — |
| May 20, 2026 | Melinda Brown Director | Option exercise | +21,000 | — | — |
| May 20, 2026 | Shari Lisa Pire Director | Option exercise | +21,000 | — | — |
| May 20, 2026 | Geno J. Germano Director | Option exercise | +21,000 | — | — |
| Feb 18, 2026 | Michael Amoroso Director, Officer (President and CEO) | Open-market sale | −20,559 | $3.84 | $78,947 |
| Feb 18, 2026 | Kelly John Alexander Officer (Chief Financial Officer) | Open-market sale | −8,149 | $3.84 | $31,292 |
| Feb 18, 2026 | Scimeca Dario Officer (General Counsel and Secretary) | Open-market sale | −4,925 | $3.84 | $18,912 |
| Feb 18, 2026 | SMITH J. JEFFERSON Officer (Chief Research Officer) | Open-market sale | −4,925 | $3.84 | $18,912 |
| Feb 17, 2026 | Michael Amoroso Director, Officer (President and CEO) | Option exercise | +67,797 | — | — |
| Feb 17, 2026 | Kelly John Alexander Officer (Chief Financial Officer) | Option exercise | +27,584 | — | — |
| Feb 17, 2026 | Scimeca Dario Officer (General Counsel and Secretary) | Option exercise | +16,667 | — | — |
| Feb 17, 2026 | SMITH J. JEFFERSON Officer (Chief Research Officer) | Option exercise | +16,667 | — | — |
| Jan 22, 2026 | Michael Amoroso Director, Officer (President and CEO) | Open-market sale | −34,799 | $4.17 | $145,112 |
| Jan 21, 2026 | SMITH J. JEFFERSON Officer (Chief Research Officer) | Option exercise | +16,219 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.